Orteronel [566939-85-3]

TargetMol Chemicals

Orteronel [566939-85-3]

14

566939-85-3

Research Use Only

Orteronel

C18H17N3O2

307.35

Orteronel ((S)-Orteronel)(TAK-700) was selected as a candidate for clinical evaluation. orteronel (TAK-700) is currently in phase III clinical trials for the treatment of castration-resistant prostate cancer.

3 years

CNC(=O)c1ccc2cc(ccc2c1)[C@@]1(O)CCn2cncc12

-20°C

12352200